US 12,419,924 B2
Methods for combining adoptive T cell therapy with oncolytic virus adjunct therapy
Gary Wood, Olathe, KS (US); and Jochen Harald Stritzker, La Jolla, CA (US)
Assigned to TVAX Biomedical I, LLC, Olathe, KS (US)
Filed by TVAX Biomedical I, LLC, Olathe, KS (US)
Filed on Apr. 5, 2023, as Appl. No. 18/295,994.
Application 18/295,994 is a continuation of application No. 16/939,266, filed on Jul. 27, 2020, granted, now 11,633,442.
Application 16/939,266 is a continuation of application No. 15/757,687, abandoned, previously published as PCT/US2016/050994, filed on Sep. 9, 2016.
Claims priority of provisional application 62/323,065, filed on Apr. 15, 2016.
Claims priority of provisional application 62/255,294, filed on Nov. 13, 2015.
Claims priority of provisional application 62/216,062, filed on Sep. 9, 2015.
Claims priority of provisional application 62/216,046, filed on Sep. 9, 2015.
Prior Publication US 2023/0233631 A1, Jul. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/68 (2006.01); A61K 35/17 (2015.01); A61K 35/76 (2015.01); A61K 35/768 (2015.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 35/768 (2013.01) [A61K 35/17 (2013.01); A61K 35/76 (2013.01); A61K 39/0011 (2013.01); A61P 35/00 (2018.01); A61K 2039/5158 (2013.01); A61K 2039/545 (2013.01); Y02A 50/30 (2018.01)] 16 Claims
 
1. A cancer immunotherapy method for treating cancer in a patient comprising:
combining an oncolytic virus with a vaccine comprised of the patient's own malignancy and vaccinating the patient with the combined virus/malignancy vaccine;
after said step of vaccinating, isolating primed T lymphocytes from lymphoid tissue, peripheral blood or cancer tissue of the patient;
stimulating the primed T lymphocytes to differentiate into effector T lymphocytes in vitro;
stimulating the effector T lymphocytes to proliferate in vitro;
and
infusing the effector T lymphocytes back into the patient after said administering step.